Brief debrisoquin administration to assess central dopaminergic function in children

Mark A. Riddle; Bennett A. Shaywitz; James F. Leckman; George M. Anderson; Sally E. Shaywitz; Maureen T. Hardin; Sharon I. Ort; Donald J. Cohen

doi:10.1016/0024-3205(86)90239-0

Brief debrisoquin administration to assess central dopaminergic function in children

Mark A. Riddle, Bennett A. Shaywitz, James F. Leckman, George M. Anderson, Sally E. Shaywitz, Maureen T. Hardin, Sharon I. Ort, Donald J. Cohen

Research output: Contribution to journal › Article › peer-review

Abstract

Central dopaminergic (DA) function in children was assessed by monitoring plasma-free homovanillic acid (pHVA) levels after brief (18 hour) administration with debrisoquin sulfate, a peripherally active antihypertensive agent that blocks peripheral, but not central, HVA production. Brief debrisoquin administration resulted in marked reductions in pHVA in each of six patients studied. In five of the six patients, post-debrisoquin pHVA levels remained relatively stable over the six-hour period of observation. No significant cardiovascular or behavioral side effects of debrisoquin were observed. The brief debrisoquin administration method appears to be a safe, simple, and potentially valid peripheral technique for evaluating aspects of central dopaminergic function in children with neuropsychiatric disorders. Additional work is needed to further establish this method's validity and reliability.

Original language	English (US)
Pages (from-to)	1041-1048
Number of pages	8
Journal	Life Sciences
Volume	38
Issue number	11
DOIs	https://doi.org/10.1016/0024-3205(86)90239-0
State	Published - Mar 17 1986
Externally published	Yes

ASJC Scopus subject areas

Biochemistry, Genetics and Molecular Biology(all)
Pharmacology, Toxicology and Pharmaceutics(all)

Access to Document

10.1016/0024-3205(86)90239-0

Fingerprint Dive into the research topics of 'Brief debrisoquin administration to assess central dopaminergic function in children'. Together they form a unique fingerprint.

Cite this

@article{a32d98901192415e8b3a40cb1d8e68a4,

title = "Brief debrisoquin administration to assess central dopaminergic function in children",

abstract = "Central dopaminergic (DA) function in children was assessed by monitoring plasma-free homovanillic acid (pHVA) levels after brief (18 hour) administration with debrisoquin sulfate, a peripherally active antihypertensive agent that blocks peripheral, but not central, HVA production. Brief debrisoquin administration resulted in marked reductions in pHVA in each of six patients studied. In five of the six patients, post-debrisoquin pHVA levels remained relatively stable over the six-hour period of observation. No significant cardiovascular or behavioral side effects of debrisoquin were observed. The brief debrisoquin administration method appears to be a safe, simple, and potentially valid peripheral technique for evaluating aspects of central dopaminergic function in children with neuropsychiatric disorders. Additional work is needed to further establish this method's validity and reliability.",

author = "Riddle, {Mark A.} and Shaywitz, {Bennett A.} and Leckman, {James F.} and Anderson, {George M.} and Shaywitz, {Sally E.} and Hardin, {Maureen T.} and Ort, {Sharon I.} and Cohen, {Donald J.}",

note = "Funding Information: The research was supported In part by USPHS grant 5-F32-MHO9109, MHCRC grant MH30929, NIH grant RR00125, NICHD grant HDO30OB, the Tourette Syndrome Association, the Solomon R. & Rebecca D. Baker Foundation, Inc., Mr. Leonard Ber-get, the Gateposts Foundation, and the John Merck Fund. Copyright: Copyright 2014 Elsevier B.V., All rights reserved.",

year = "1986",

month = mar,

day = "17",

doi = "10.1016/0024-3205(86)90239-0",

language = "English (US)",

volume = "38",

pages = "1041--1048",

journal = "Life Sciences",

issn = "0024-3205",

publisher = "Elsevier Inc.",

number = "11",

}

TY - JOUR

T1 - Brief debrisoquin administration to assess central dopaminergic function in children

AU - Riddle, Mark A.

AU - Shaywitz, Bennett A.

AU - Leckman, James F.

AU - Anderson, George M.

AU - Shaywitz, Sally E.

AU - Hardin, Maureen T.

AU - Ort, Sharon I.

AU - Cohen, Donald J.

N1 - Funding Information: The research was supported In part by USPHS grant 5-F32-MHO9109, MHCRC grant MH30929, NIH grant RR00125, NICHD grant HDO30OB, the Tourette Syndrome Association, the Solomon R. & Rebecca D. Baker Foundation, Inc., Mr. Leonard Ber-get, the Gateposts Foundation, and the John Merck Fund. Copyright: Copyright 2014 Elsevier B.V., All rights reserved.

PY - 1986/3/17

Y1 - 1986/3/17

N2 - Central dopaminergic (DA) function in children was assessed by monitoring plasma-free homovanillic acid (pHVA) levels after brief (18 hour) administration with debrisoquin sulfate, a peripherally active antihypertensive agent that blocks peripheral, but not central, HVA production. Brief debrisoquin administration resulted in marked reductions in pHVA in each of six patients studied. In five of the six patients, post-debrisoquin pHVA levels remained relatively stable over the six-hour period of observation. No significant cardiovascular or behavioral side effects of debrisoquin were observed. The brief debrisoquin administration method appears to be a safe, simple, and potentially valid peripheral technique for evaluating aspects of central dopaminergic function in children with neuropsychiatric disorders. Additional work is needed to further establish this method's validity and reliability.

AB - Central dopaminergic (DA) function in children was assessed by monitoring plasma-free homovanillic acid (pHVA) levels after brief (18 hour) administration with debrisoquin sulfate, a peripherally active antihypertensive agent that blocks peripheral, but not central, HVA production. Brief debrisoquin administration resulted in marked reductions in pHVA in each of six patients studied. In five of the six patients, post-debrisoquin pHVA levels remained relatively stable over the six-hour period of observation. No significant cardiovascular or behavioral side effects of debrisoquin were observed. The brief debrisoquin administration method appears to be a safe, simple, and potentially valid peripheral technique for evaluating aspects of central dopaminergic function in children with neuropsychiatric disorders. Additional work is needed to further establish this method's validity and reliability.

UR - http://www.scopus.com/inward/record.url?scp=0022601257&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022601257&partnerID=8YFLogxK

U2 - 10.1016/0024-3205(86)90239-0

DO - 10.1016/0024-3205(86)90239-0

M3 - Article

C2 - 3456480

AN - SCOPUS:0022601257

VL - 38

SP - 1041

EP - 1048

JO - Life Sciences

JF - Life Sciences

SN - 0024-3205

IS - 11

ER -

Brief debrisoquin administration to assess central dopaminergic function in children

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this